|
C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Ipsen; Merck; Novartis; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Bayer; Celgene; Novartis; Sanofi |
Research Funding - Amgen; Ipsen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen; EMD Serono; Merck; Roche Pharma AG; Taiho Pharmaceutical |
|
|
Research Funding - Swedish Cancer Society (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |